| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | BIOMARKERS FOR USE IN DETERMINING RESPONSE TO TREATMENT OF NEURODEGENERATION DISEASE | US16333979 | 2017-09-14 | US20190212344A1 | 2019-07-11 | Marie-Helene Dziesietnik; Daria Mochly-Rosen |
| The diagnosis of a neurodegenerative disease or the response of a patient with a neurodegenerative disease to therapy, in a clinical trial setting or in a long-term disease management setting, is assessed. | ||||||
| 2 | デュシェンヌ型筋ジストロフィーを治療するためのダイナミン2阻害剤 | JP2017555366 | 2016-04-22 | JP2018518456A | 2018-07-12 | ジョスラン・ラポルテ; ベリンダ・コウリング |
| 本開示は、デュシェンヌ型筋ジストロフィーの治療における使用のためのダイナミン2の阻害剤又はそれを含む組成物に関する。 | ||||||
| 3 | 中心核ミオパシーを治療するためのダイナミン２阻害剤 | JP2016524149 | 2014-10-20 | JP2016540732A | 2016-12-28 | ジョスリン・ラポルテ; ベリンダ・カウリング; ヒチェム・タスファウ |
| 本開示は、中心核ミオパシーの治療における使用のためのダイナミン2阻害剤に関する。本開示は、ダイナミン2阻害剤を含有する医薬組成物、及び中心核ミオパシーの治療を目的としたその使用にも関する。また、本開示は、中心核ミオパシーの治療で有用な分子を識別又はスクリーニングする方法も扱う。 | ||||||
| 4 | DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY | EP15305615.5 | 2015-04-22 | EP3085785A1 | 2016-10-26 | Laporte, Jocelyn; Cowling, Belinda |
The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy.
|
||||||
| 5 | DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES | US15030127 | 2014-10-20 | US20160264976A1 | 2016-09-15 | JOCELYN LAPORTE; BELINDA COWLING; HICHEM TASFAOUT |
| The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy. | ||||||
| 6 | Dynamin mediated diseases and associated methods and products | US12693858 | 2010-01-26 | US08668927B2 | 2014-03-11 | Jochen Reiser; Sanja Sever |
| This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer. | ||||||
| 7 | Dynamin mediated diseases and associated methods and products | US11594003 | 2006-11-07 | US07670817B2 | 2010-03-02 | Jochen Reiser; Sanja Sever |
| This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer. | ||||||
| 8 | AGENTS FOR PROPHYLAXIS OR TREATMENT OF NEUROLOGICAL RELATED DISEASES AND CONDITIONS | US12112359 | 2008-04-30 | US20080306007A1 | 2008-12-11 | Adam McCluskey; Phillip Robinson; Michael Cousin |
| Inhibitors of syndapin I binding to dynamin I (DynI) are provided. Examples include mimetics of a region of DynI including the serine residues S774 and S778 or phosphorylatable amino acids in homologous positions. Typically, the mimetics exclude or do not imitate at least one phosphorylation site provided by the serine residues or phosphorylatable amino acids. Peptide fragment inhibitors comprising or consisting of this region of DynI are also described. The inhibitors have application in the prophylaxis or treatment of neurological diseases or conditions. The inhibitors can also be used to inhibit neuronal cell vesicle trafficking and synaptic signal transmission. | ||||||
| 9 | Designing Customized Protein-Specific Buffer System | US15761936 | 2016-09-22 | US20180282782A1 | 2018-10-04 | Shawn CLARK; Jeffrey SIGNOR |
| The present invention is related to the field of protein chemistry. In particular, mixed buffer compositions are formulated that allow an accurate identification of agent-induced changes in protein melting point temperatures. Such buffer compositions provide for methods that determine the specific effects of exogenous agents on protein stability, cryoprotective effects and/or protein quality control (e.g., synthesis and/or extraction purity validations). | ||||||
| 10 | DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY | US15568007 | 2016-04-22 | US20180142008A1 | 2018-05-24 | JOCELYN LAPORTE; BELINDA COWLING |
| The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy. | ||||||
| 11 | DYNAMIN MEDIATED DISEASES AND ASSOCIATED METHODS AND PRODUCTS | US12693858 | 2010-01-26 | US20100221317A1 | 2010-09-02 | Jochen Reiser; Sanja Sever |
| This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer. | ||||||
| 12 | Dynamin mediated diseases and associated methods and products | US11594003 | 2006-11-07 | US20070197438A1 | 2007-08-23 | Jochen Reiser; Sanja Sever |
| This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer. | ||||||
| 13 | DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY | EP16722076 | 2016-04-22 | EP3286317A1 | 2018-02-28 | LAPORTE JOCELYN; COWLING BELINDA |
| The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy. | ||||||
| 14 | DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES | EP14786893.9 | 2014-10-20 | EP3058071B1 | 2018-08-15 | LAPORTE, Jocelyn; COWLING, Belinda; TASFAOUT, Hichem |
| The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy. | ||||||
| 15 | DESIGNING CUSTOMIZED PROTEIN-SPECIFIC BUFFER SYSTEMS | EP16849595.0 | 2016-09-22 | EP3353547A1 | 2018-08-01 | CLARK, Shawn; SIGNOR, Jeffrey |
| The present invention is related to the field of protein chemistry. In particular, mixed buffer compositions are formulated that allow an accurate identification of agent-induced changes in protein melting point temperatures. Such buffer compositions provide for methods that determine the specific effects of exogenous agents on protein stability, cryoprotective effects and/or protein quality control (e.g., synthesis and/or extraction purity validations). | ||||||
| 16 | DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHIES | EP14786893.9 | 2014-10-20 | EP3058071A1 | 2016-08-24 | LAPORTE, Jocelyn; COWLING, Belinda; TASFAOUT, Hichem |
| The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy. | ||||||
| 17 | Dynamin 2 inhibitor for the treatment of centronuclear myopathies | EP13306440.2 | 2013-10-18 | EP2862928A1 | 2015-04-22 | Laporte, Jocelyn; Cowling, Belinda |
The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy. |
||||||
| 18 | PROTEINS CONTAINING EXPANDED POLYGLUTAMINE TRACTS INDUCE MITOCHONDRIAL FRAGMENTATION BY DISRUPTING MITOCHONDRIAL FUSION | PCT/US2009051315 | 2009-07-21 | WO2010011693A3 | 2010-04-29 | MONTEIRO MERVYN J; WANG HONGMIN |
| Expanded polyglutamine tracts are shown to be a cause of disturbance of mitochondrial function and therefore a cause of cell toxicity and cell death and a cause of various diseases or disorders related to such effects. Such diseases and disorders may include neurodegenerative diseases or disorders, such as Huntington's Disease, Spinocerebellar ataxias, spinal and bulbar muscular atrophy, and dentatorubral-pallidoluysian atrophy. Methods for controlling such cell death, cell toxicity and/or related diseases or disorders are described. Also described is treatment of such neurodegenerative diseases or disorders. | ||||||
| 19 | DYNAMIN MEDIATED DISEASES AND ASSOCIATED METHODS AND PRODUCTS | PCT/US2006043445 | 2006-11-07 | WO2007056435A3 | 2008-03-27 | REISER JOCHEN; SEVER SANJA |
| This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer. | ||||||
QQ群二维码
意见反馈
意见反馈